SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026FDA cleared the Company’s IND application for a planned registrational path study of tegoprubart in islet cell transplantation for patients with type 1 diabetesFDA Fast Track designat…

ELDN

Related stories